

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	43060-706.201
	First Named Inventor	Gerold L. Mosher
	Title	Lisinopril Formulations
	Express Mail Label No.	Filed Electronically on November 6, 2015

<b>APPLICATION ELEMENTS</b> <i>See MPEP chapter 600 concerning utility patent application contents.</i>	<b>ADDRESS TO:</b> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
--	--

<p>1. <input type="checkbox"/> <b>Fee Transmittal Form</b> (PTO/SB/17 or equivalent)</p> <p>2. <input type="checkbox"/> <b>Applicant asserts small entity status.</b> See 37 CFR 1.27</p> <p>3. <input type="checkbox"/> <b>Applicant certifies micro entity status.</b> See 37 CFR 1.29. Applicant must attach form PTO/SB/15A or B or equivalent.</p> <p>4. <input checked="" type="checkbox"/> <b>Specification</b> [Total Pages <u>49</u>] Both the claims and abstract must start on a new page. (See MPEP § 608.01(a) for information on the preferred arrangement)</p> <p>5. <input checked="" type="checkbox"/> <b>Drawings(s)</b> (35 U.S.C. 113) [Total Sheets <u>2</u>]</p> <p>6. <b>Inventor's Oath or Declaration</b> [Total Pages <u>2</u>] (including substitute statements under 37 CFR 1.64 and assignments serving as an oath or declaration under 37 CFR 1.63(e))</p> <p>a. <input checked="" type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> A copy from a prior application (37 CFR 1.63(d))</p> <p>7. <input checked="" type="checkbox"/> <b>Application Data Sheet</b> * See note below. See 37 CFR 1.76 (PTO/AIA/14 or equivalent)</p> <p>8. <b>CD-ROM or CD-R</b> in duplicate, large table, or Computer Program (Appendix)</p> <p><input type="checkbox"/> Landscape Table on CD</p> <p>9. <b>Nucleotide and/or Amino Acid Sequence Submission</b> (if applicable, items a. - c. are required)</p> <p>a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. <input type="checkbox"/> Specification Sequence Listing on:</p> <p>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p>ii. <input type="checkbox"/> Paper</p> <p>c. <input type="checkbox"/> Statements verifying identity of above copies</p>	<p style="text-align: center;"><b>ACCOMPANYING APPLICATION PAPERS</b></p> <p>10. <input type="checkbox"/> <b>Assignment Papers</b> (cover sheet &amp; document(s)) Name of Assignee <u>Silvergate Pharmaceuticals, Inc.</u></p> <p>11. <input checked="" type="checkbox"/> <b>37 CFR 3.73(c) Statement</b> <input checked="" type="checkbox"/> <b>Power of Attorney</b> (when there is an assignee)</p> <p>12. <input type="checkbox"/> <b>English Translation Document</b> (if applicable)</p> <p>13. <input type="checkbox"/> <b>Information Disclosure Statement</b> (PTO/SB/08 or PTO-1449) <input type="checkbox"/> Copies of citations attached</p> <p>14. <input type="checkbox"/> <b>Preliminary Amendment</b></p> <p>15. <input type="checkbox"/> <b>Return Receipt Postcard</b> (MPEP § 503) (Should be specifically itemized)</p> <p>16. <input type="checkbox"/> <b>Certified Copy of Priority Document(s)</b> (if foreign priority is claimed)</p> <p>17. <input type="checkbox"/> <b>Nonpublication Request</b> Under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent.</p> <p>18. <input checked="" type="checkbox"/> <b>Other:</b> Certification and Request for Prioritized Examination Under 37 CFR 1.102(e) (1pp) Request for First Action Interview (1pp) Copy of Assignment from parent application (2 pp)</p>
---	--

\*Note: (1) Benefit claims under 37 CFR 1.78 and foreign priority claims under 1.55 must be included in an Application Data Sheet (ADS).  
(2) For applications filed under 35 U.S.C. 111, the application must contain an ADS specifying the applicant if the applicant is an assignee, person to whom the inventor is under an obligation to assign, or person who otherwise shows sufficient proprietary interest in the matter. See 37 CFR 1.46(b).

<b>19. CORRESPONDENCE ADDRESS</b>				
<input checked="" type="checkbox"/> The address associated with Customer Number: <u>21971</u> OR <input type="checkbox"/> Correspondence address below				
Name				
Address				
City	State	Zip Code		
Country	Telephone	Email		

Signature	/Clark Lin/	Date	November 6, 2015
Name (Print/Type)	Clark Y. Lin	Registration No. (Attorney/Agent)	67024

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

UNITED STATES PATENT APPLICATION

**LISINOPRIL FORMULATIONS**

Inventors: Gerold L. Mosher,  
Citizen of the United States of America, Residing at  
12215 Avila Drive  
Kansas City, MO 64145

David W. Miles,  
Citizen of the United States of America, Residing at  
12309 Wyandotte Street  
Kansas City, MO 64145

Assignee: Silvergate Pharmaceuticals, Inc.  
6251 Greenwood Plaza Blvd., Suite 101  
Greenwood Village, CO 80111

a Delaware Corporation

Entity: Large business concern



Wilson Sonsini Goodrich & Rosati

PROFESSIONAL CORPORATION

650 Page Mill Road  
Palo Alto, CA 94304  
(650) 493-9300 (Main)  
(650) 493-6811 (Facsimile)

**Filed Electronically on: November 6, 2015**


## LISINOPRIL FORMULATIONS

### BACKGROUND OF THE INVENTION

[0001] Hypertension, or high blood pressure, is a serious health issue in many countries. According to the National Heart Blood and Lung Institute, it is thought that about 1 in 3 adults in the United States alone have hypertension. Left unchecked, hypertension is considered a substantial risk factor for cardiovascular and other diseases including coronary heart disease, myocardial infarction, congestive heart failure, stroke and kidney failure. Hypertension is classified as primary (essential) hypertension or secondary hypertension. Primary hypertension has no known cause and may be related to a number of environmental, lifestyle and genetic factors such as stress, obesity, smoking, inactivity and sodium intake. Secondary hypertension can be caused by drug or surgical interventions or by abnormalities in the renal, cardiovascular or endocrine system.

[0002] A number of antihypertensive drugs are available for treating hypertension. Various therapeutic classes of antihypertensive drugs include alpha-adrenergic blockers, beta-adrenergic blockers, calcium-channel blockers, hypotensives, mineralcorticoid antagonists, central alpha-agonists, diuretics and rennin-angiotensin-aldosterone inhibitors which include angiotensin II receptor antagonists (ARB) and angiotensin-converting enzyme (ACE) inhibitors. Angiotensin-converting enzyme (ACE) inhibitors inhibit angiotensin-converting enzyme (ACE), a peptidyl dipeptidase that catalyzes angiotensin I to angiotensin II, a potent vasoconstrictor involved in regulating blood pressure.

[0003] Lisinopril is a drug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. Lisinopril IUPAC name is N<sup>2</sup>-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline. Its structural formula is as follows:



Lisinopril

[0004] Lisinopril is currently administered in the form of oral tablets, (e.g., Prinivil®, Zestril®). In addition to the treatment of hypertension, lisinopril tablets have been used for the treatment of heart failure and acute myocardial infarction.

## SUMMARY OF THE INVENTION

[0005] Provided herein are lisinopril oral liquid formulations. In one aspect, the lisinopril oral liquid formulation comprises (i) lisinopril or a pharmaceutically acceptable salt or solvate thereof, (ii) a sweetener that is xylitol, (iii) a buffer comprising citric acid (iv) a preservative that is sodium benzoate, and (v) water; wherein the pH of the formulation is between about 4 and about 5; and wherein the formulation is stable at about  $25\pm 5$  °C for at least 12 months.

[0006] In some embodiments, the lisinopril is lisinopril dihydrate. In some embodiments, the formulation further comprises a flavoring agent. In some embodiments, the formulation further comprises a second sweetener. In some embodiments, the second sweetener is sodium saccharin or sucralose. In some embodiments, the pH is about 4.9. In some embodiments, the formulation is stable at about  $25\pm 5$  °C for at least 18 months. In some embodiments, the formulation is stable at about  $25\pm 5$  °C for at least 24 months. In some embodiments, the buffer further comprises sodium citrate.

[0007] In some embodiments, the amount of lisinopril or a pharmaceutically acceptable salt or solvate thereof is about 0.8 to about 1.2 mg/ml. In some embodiments, the amount of xylitol is about 140 to about 160 mg/ml. In some embodiments, the amount of citric acid in the buffer is about 0.5 to about 1.2 mg/ml. In some embodiments, the amount of sodium citrate in the buffer is about 1.2 to about 1.7 mg/ml. In some embodiments, the amount of the sodium benzoate is about 0.5 to about 1.2 mg/ml.

[0008] In one aspect, the lisinopril oral liquid formulation comprises (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof, (ii) about 150 mg/ml of a sweetener that is xylitol, (iii) a buffer comprising about 0.86 mg/ml citric acid, (iv) about 0.8 mg/ml of a preservative that is sodium benzoate; and (v) water; wherein the pH of the formulation is between about 4 and about 5; and wherein the formulation is stable at about  $25\pm 5$  °C for at least 12 months.

[0009] In some embodiments, the lisinopril is lisinopril dihydrate. In some embodiments, the formulation further comprises a flavoring agent. In some embodiments, the formulation further comprises a second sweetener. In some embodiments, the second sweetener is sodium saccharin or sucralose. In some embodiments, the pH is about 4.9. In some embodiments, the formulation is stable at about  $25\pm 5$  °C for at least 18 months. In some embodiments, the formulation is stable at about  $25\pm 5$  °C for at least 24 months. In some embodiments, the buffer further comprises sodium citrate. In some embodiments, the buffer further comprises about 1.44 mg/ml sodium citrate.

[0010] In some embodiments, the amount of lisinopril or a pharmaceutically acceptable salt or solvate thereof is about 0.5 to about 1 % (w/w of solids). In some embodiments, the amount of xylitol is about 95 to about 98 % (w/w of solids). In some embodiments, the amount of citric acid in the buffer is about 0.3 to about 0.7 % (w/w of solids). In some embodiments, the amount of sodium citrate in the buffer is about

0.7 to about 1.3 % (w/w of solids). In some embodiments, the amount of sodium benzoate is about 0.4 to about 1.2 % (w/w of solids).

**[0011]** In another aspect, the lisinopril oral liquid formulation comprises (i) about 0.7 % (w/w of solids) lisinopril or a pharmaceutically acceptable salt or solvate thereof, (ii) about 97.3 % (w/w of solids) of a sweetener that is xylitol, (iii) a buffer comprising about 0.01 molar citrate, (iv) about 0.52 % (w/w of solids) of a preservative that is sodium benzoate, and (v) water; wherein the pH of the formulation is between about 4 and about 5; and wherein the formulation is stable at about 25±5 °C for at least 12 months.

**[0012]** In some embodiments, the lisinopril is lisinopril dihydrate. In some embodiments, the formulation further comprises a flavoring agent. In some embodiments, the formulation further comprises a second sweetener. In some embodiments, the second sweetener is sodium saccharin or sucralose. In some embodiments, the pH is about 4.9. In some embodiments, the formulation is stable at about 25±5 °C for at least 18 months. In some embodiments, the formulation is stable at about 25±5 °C for at least 24 months. In some embodiments, the buffer comprises citric acid and sodium citrate.

**[0013]** In another aspect, the lisinopril oral liquid formulation consists of (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof, (ii) about 150 mg/ml of a sweetener that is xylitol, (iii) a buffer comprising about 0.86 mg/ml citric acid and about 1.44 mg/ml sodium citrate, (iv) about 0.8 mg/ml of a preservative that is sodium benzoate, (v) and water; wherein the pH of the formulation is between about 4 and about 5 adjusted by sodium hydroxide or hydrochloric acid; and wherein the formulation is stable at about 25±5 °C for at least 12 months. In some embodiments, the formulation is stable at about 25±5 °C for at least 24 months. In some embodiments, the pH is about 4.9.

**[0014]** Also provided herein are methods of treating hypertension comprising administering to a patient in need thereof a lisinopril oral liquid formulation described herein. In some embodiments, the hypertension is primary (essential) hypertension. In some embodiments, the hypertension is secondary hypertension. In some embodiments, the subject with hypertension has blood pressure values greater than or equal to 140/90 mm Hg.

**[0015]** Also provided herein are methods of treating prehypertension comprising administering to a patient in need thereof a lisinopril oral liquid formulation described herein. In some embodiments, the subject with prehypertension has blood pressure values of about 120-139/80-89 mm Hg.

**[0016]** Also provided herein are methods of treating heart failure or acute myocardial infarction comprising administering to a patient in need thereof a lisinopril oral liquid formulation described herein.

**[0017]** In some embodiments, the subject is an adult. In some embodiments, the subject is elderly. In some embodiments, the subject is a child. In some embodiments, the lisinopril oral liquid formulation is

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.